{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:18:12Z","timestamp":1788923892850,"version":"build-2803163510"},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pure red cell aplasia (PRCA) is a syndrome defined by a normocytic normochromic anemia with severe reticulocytopenia and marked reduction or absence of erythroid precursors from the bone marrow. Diamond-Blackfan anemia is a congenital form of PRCA. Acquired PRCA may be either a primary disorder or secondary to some other disorder or agent. Primary acquired PRCA is an autoimmune disorder that is frequently antibody-mediated. Myelodysplastic syndromes may also present with the morphologic appearance of PRCA. Secondary acquired PRCA may be associated with collagen vascular\/autoimmune disorders such as systemic lupus erythematosus; lymphoproliferative disorders such as chronic lymphocytic leukemia or large granular lymphocyte leukemia; infections, particularly B19 parvovirus; thymoma and other solid tumors; or a variety of other disorders, drugs, or toxic agents. The therapeutic approach to PRCA typically involves immunosuppression, but specific pathogenic subtypes are associated with specific therapeutic approaches. Cyclosporine A, with or without concurrent corticosteroids, appears to be the single most effective immunosuppressive agent.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.51","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Pure red cell aplasia"],"prefix":"10.1182","volume":"2016","author":[{"suffix":"Jr","given":"Robert T.","family":"Means","sequence":"first","affiliation":[{"name":"Office of the Dean, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111704002524100_B1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2141.2008.07216.x","article-title":"Acquired pure red cell aplasia: updated review of treatment","volume":"142","author":"Sawada","year":"2008","journal-title":"Br J Haematol"},{"issue":"18","key":"2019111704002524100_B2","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood-2014-04-526301","article-title":"Marrow failure: a window into ribosome biology","volume":"124","author":"Ruggero","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111704002524100_B3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/shem.2002.35637","article-title":"The genetics of inherited sideroblastic anemias","volume":"39","author":"Fleming","year":"2002","journal-title":"Semin Hematol"},{"key":"2019111704002524100_B4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1365-2141.1991.tb04392.x","article-title":"Treatment of refractory pure red cell aplasia with cyclosporine A: disappearance of IgG inhibitor associated with clinical response","volume":"78","author":"Means","year":"1991","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111704002524100_B5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00277-014-2192-z","article-title":"Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA)","volume":"94","author":"Cerchione","year":"2015","journal-title":"Ann Hematol"},{"issue":"7","key":"2019111704002524100_B6","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1111\/apa.12634","article-title":"Transient erythroblastopenia of childhood is an underdiagnosed and self-limiting disease","volume":"103","author":"van den Akker","year":"2014","journal-title":"Acta Paediatr"},{"issue":"2","key":"2019111704002524100_B7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2141.1981.tb08455.x","article-title":"Red cell aplasia and chronic granulocytic leukaemia","volume":"48","author":"Dessypris","year":"1981","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111704002524100_B8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2141.1994.tb06743.x","article-title":"Parvovirus B19 as a cause of acquired chronic pure red cell aplasia","volume":"87","author":"Frickhofen","year":"1994","journal-title":"Br J Haematol"},{"issue":"17","key":"2019111704002524100_B9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJM199404283301704","article-title":"Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen)","volume":"330","author":"Brown","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111704002524100_B10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.beha.2005.01.015","article-title":"Clinical characteristics of erythropoietin-associated pure red cell aplasia","volume":"18","author":"Carson","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"12","key":"2019111704002524100_B11","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s11606-012-2098-1","article-title":"Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye\u2019s syndrome. a report from the Southern Network on Adverse Reactions (SONAR)","volume":"27","author":"Bennett","year":"2012","journal-title":"J Gen Intern Med"},{"issue":"1","key":"2019111704002524100_B12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2015.09.005","article-title":"Thymoma associated with autoimmune diseases: 85 cases and literature review","volume":"15","author":"Bernard","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2019111704002524100_B13","volume-title":"Pure red cell aplasia","author":"Dessypris","year":"1988"},{"issue":"6","key":"2019111704002524100_B14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.13376","article-title":"Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004\/2006 by the Japan PRCA collaborative study group","volume":"169","author":"Hirokawa","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111704002524100_B15","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.12871","article-title":"Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group","volume":"93","author":"Fujishima","year":"2008","journal-title":"Haematologica"},{"issue":"11","key":"2019111704002524100_B16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23785","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia","volume":"89","author":"Visco","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111704002524100_B17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/ajh.20374","article-title":"Clonal T cells of pure red-cell aplasia","volume":"79","author":"Masuda","year":"2005","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111704002524100_B18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajh.21354","article-title":"Acquired pure red cell aplasia associated with malignant lymphomas: a nationwide cohort study in Japan for the PRCA Collaborative Study Group","volume":"84","author":"Hirokawa","year":"2009","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111704002524100_B19","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/j.1875-9114.1996.tb03025.x","article-title":"Drug-induced pure red cell aplasia","volume":"16","author":"Thompson","year":"1996","journal-title":"Pharmacotherapy"},{"issue":"4","key":"2019111704002524100_B20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V65.4.789.bloodjournal654789","article-title":"Diphenylhydantoin-induced pure red cell aplasia","volume":"65","author":"Dessypris","year":"1985","journal-title":"Blood"},{"issue":"4","key":"2019111704002524100_B21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0002-9343(89)80833-2","article-title":"Rifampicin-induced pure red cell aplasia","volume":"87","author":"Mariette","year":"1989","journal-title":"Am J Med"},{"issue":"4","key":"2019111704002524100_B22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-006-0211-4","article-title":"Pure red-cell aplasia secondary to pregnancy, characterization of a syndrome","volume":"86","author":"Choudry","year":"2007","journal-title":"Ann Hematol"},{"issue":"6","key":"2019111704002524100_B23","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjh.12210","article-title":"Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation","volume":"160","author":"Aung","year":"2013","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111704002524100_B24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00277-004-0894-3","article-title":"Myelodysplasia masquerading as parvovirus-related red cell aplasia with giant pronormoblasts","volume":"83","author":"Au","year":"2004","journal-title":"Ann Hematol"},{"issue":"2","key":"2019111704002524100_B25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.seminhematol.2011.01.004","article-title":"Diamond Blackfan anemia treatment: past, present, and future","volume":"48","author":"Narla","year":"2011","journal-title":"Semin Hematol"},{"issue":"7","key":"2019111704002524100_B26","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1182\/blood.V87.7.3000.bloodjournal8773000","article-title":"Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities","volume":"87","author":"Lacy","year":"1996","journal-title":"Blood"},{"issue":"11","key":"2019111704002524100_B27","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1182\/blood.V87.11.4831.bloodjournal87114831","article-title":"The pathophysiology of pure red cell aplasia: implications for therapy","volume":"87","author":"Charles","year":"1996","journal-title":"Blood"},{"issue":"1","key":"2019111704002524100_B28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2257.2004.00654.x","article-title":"Effect of tacrolimus in a patient with pure red-cell aplasia","volume":"27","author":"Yoshida","year":"2005","journal-title":"Clin Lab Haematol"},{"issue":"3","key":"2019111704002524100_B29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1365-2141.2002.3317_3.x","article-title":"Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment","volume":"116","author":"Auner","year":"2002","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111704002524100_B30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-0609.2008.01187.x","article-title":"Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia","volume":"82","author":"D\u2019Arena","year":"2009","journal-title":"Eur J Haematol"},{"issue":"5","key":"2019111704002524100_B31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.autrev.2004.10.004","article-title":"Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia","volume":"4","author":"Mouthon","year":"2005","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2019111704002524100_B32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1600-0609.1985.tb01711.x","article-title":"Complete remission in pure red cell aplasia after plasmapheresis","volume":"35","author":"Freund","year":"1985","journal-title":"Scand J Haematol"},{"issue":"2","key":"2019111704002524100_B33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood.V46.2.261.bloodjournal462261","article-title":"Studies on pure red cell aplasia. VII. Presence of proerythroblasts and response to splenectomy: a case report","volume":"46","author":"Zaentz","year":"1975","journal-title":"Blood"},{"issue":"1","key":"2019111704002524100_B34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/sj.bmt.1704993","article-title":"Reduced intensity conditioning bone marrow transplantation for pure red cell aplasia: successful outcome but difficult post transplant course","volume":"36","author":"Kochethu","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111704002524100_B35","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/cid\/cis1046","article-title":"Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature","volume":"56","author":"Crabol","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2019111704002524100_B36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2141.2006.06295.x","article-title":"Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience","volume":"135","author":"Thompson","year":"2006","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111704002524100_B37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3324\/haematol.11655","article-title":"Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group","volume":"93","author":"Hirokawa","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2019111704002524100_B38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000441507","article-title":"ABO-mismatched allogeneic hematopoietic stem cell transplantation","volume":"43","author":"Worel","year":"2016","journal-title":"Transfus Med Hemother"},{"issue":"3","key":"2019111704002524100_B39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/ndt\/gfu297","article-title":"Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)","volume":"30","author":"Macdougall","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2019111704002524100_B40","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/ki.2011.500","article-title":"Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights","volume":"81","author":"Macdougall","year":"2012","journal-title":"Kidney Int"},{"issue":"2","key":"2019111704002524100_B41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000328041","article-title":"Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin","volume":"126","author":"Shimizu","year":"2011","journal-title":"Acta Haematol"},{"issue":"1","key":"2019111704002524100_B42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00404-014-3184-x","article-title":"Newly diagnosed adult-onset Still\u2019s disease with pure red cell aplasia in pregnancy","volume":"290","author":"Moussa","year":"2014","journal-title":"Arch Gynecol Obstet"},{"issue":"7","key":"2019111704002524100_B43","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3109\/01443615.2010.501919","article-title":"Maternal and fetal outcome in pregnancy-associated pure red cell aplasia","volume":"30","author":"Kashyap","year":"2010","journal-title":"J Obstet Gynaecol"},{"key":"2019111704002524100_B44","first-page":"975","article-title":"Red cell aplasia: acquired and congenital disorders","author":"Lipton","year":"2013","journal-title":"Wintrobe\u2019s Clinical Hematology"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/51\/1250256\/hem088416.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/51\/1250256\/hem088416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T23:47:10Z","timestamp":1718927230000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/51\/21021\/Pure-red-cell-aplasia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.51","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}